drugset / Trial / NCT01161602

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)

NCT01161602 ↗

Phase 2 Completed Edusa Pharmaceuticals, Inc.

Summary

The purpose of this study is to determine if pumosetrag is effective in treating Gastroesophageal Reflux Disease (GERD) symptoms in patients who have a history of GERD symptoms and are currently taking an acid suppression therapy, such as a Proton Pump Inhibitor (PPI).

Timeline

Start
—
Primary completion
—
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pumosetrag Unknown 0.2 mg —
Subject Pumosetrag Unknown 0.5 mg —
Subject Pumosetrag Unknown 0.8 mg —